20 Dec 2024 CMB International Global Markets | Equity Research | Company Update Hansoh Pharma (3692 HK) Oral GLP-1 candidate accomplished transaction with MSD Hansoh out-licensed oral GLP-1 drug to MSD. Hansoh has granted MSD a global exclusive license for HS-10535, a preclinical stage oral small molecule GLP-1R agonist. Under the agreement, Hansoh will receive an upfront payment of US$112mn, with potential milestone payments up to US$1.9bn, plus future sales royalties. Under specific conditions, Hansoh may ...